Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu- ...
Scott T. Tagawa discusses a phase 1/2 trial (NCT04886986) investigating 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Initial findings show 225Ac-J591 is tolerable, with no dose-limiting toxicities in early cohorts, though one patient experienced grade 3 thrombocytopenia.
Related Clinical Trials
Reference News
Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu- ...
Scott T. Tagawa discusses a phase 1/2 trial (NCT04886986) investigating 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Initial findings show 225Ac-J591 is tolerable, with no dose-limiting toxicities in early cohorts, though one patient experienced grade 3 thrombocytopenia.